Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP
- Andrew L. Kung1,4,
- Vivienne I. Rebel1,4,
- Roderick T. Bronson2,
- Lian-Ee Ch'ng1,
- Colin A. Sieff1,
- David M. Livingston1,5, and
- Tso-Pang Yao3,4,5
- 1Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115 USA; 2Department of Pathology, Tufts University Schools of Medicine and Veterinary Medicine, Boston, Massachusetts 02111 USA; 3Departments of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710 USA
Abstract
Mice with monoallelic inactivation of the CBP gene develop highly penetrant, multilineage defects in hematopoietic differentiation and, with advancing age, an increased incidence of hematologic malignancies. The latter are characterized, at least in some cases, by loss of heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or p300 heterozygous null mice of the same age and genetic background. Thus, a full complement of CBP, but not p300, is required for normal hematopoietic differentiation. These results also provide the first experimental evidence for the hypothesis that CBP has tumor-suppressing activity.
